Cargando…

Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H(2)S Generation and Endothelin-1

BACKGROUND: GPBAR1 is a bile acids activated receptor expressed in entero-hepatic tissues. In the liver expression of GPBAR1 is restricted to sinusoidal and Kuppfer cells. In the systemic circulation vasodilation caused by GPBAR1 agonists is abrogated by inhibition of cystathione-γ-liase (CSE), an e...

Descripción completa

Detalles Bibliográficos
Autores principales: Renga, Barbara, Cipriani, Sabrina, Carino, Adriana, Simonetti, Michele, Zampella, Angela, Fiorucci, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634759/
https://www.ncbi.nlm.nih.gov/pubmed/26539823
http://dx.doi.org/10.1371/journal.pone.0141082
_version_ 1782399413805645824
author Renga, Barbara
Cipriani, Sabrina
Carino, Adriana
Simonetti, Michele
Zampella, Angela
Fiorucci, Stefano
author_facet Renga, Barbara
Cipriani, Sabrina
Carino, Adriana
Simonetti, Michele
Zampella, Angela
Fiorucci, Stefano
author_sort Renga, Barbara
collection PubMed
description BACKGROUND: GPBAR1 is a bile acids activated receptor expressed in entero-hepatic tissues. In the liver expression of GPBAR1 is restricted to sinusoidal and Kuppfer cells. In the systemic circulation vasodilation caused by GPBAR1 agonists is abrogated by inhibition of cystathione-γ-liase (CSE), an enzyme essential to the generation of hydrogen sulfide (H(2)S), a vasodilatory agent. Portal BAR501 is a semisynthetic bile acid derivative endowed with a potent and selective agonistic activity toward GPBAR1. METHODS: Cirrhosis was induced in mice by carbon tetrachloride (CCL(4)) administration for 9 weeks. Liver endothelial dysfunction was induced by feeding wild type and Gpbar1(-/-) mice with methionine for 4 weeks. In both models, mice were administered BAR501, 15 mg/kg/day. RESULTS: By transactivation assay we demonstrate that BAR501 is a selective GPBAR1 agonist devoid of any FXR agonistic activity. In naïve rats, BAR501 effectively reduced hepatic perfusion pressure and counteracted the vasoconstriction activity of norepinephrine. In the CCl(4) model, 9 weeks treatment with BAR501 effectively protected against development of endothelial dysfunction by increasing liver CSE expression and activity and by reducing endothelin (ET)-1 gene expression. In mice feed methionine, treatment with BAR501 attenuated endothelial dysfunction and caused a GPBAR1-dependent regulation of CSE. Using human liver sinusoidal cells, we found that modulation of CSE expression/activity is mediated by both genomic (recruitment of CREB to CRE in the CSE promoter) and non-genomic effects, involving a Akt-dependent phosporylation of CSE and endothelial nitric oxide (NO) synthase (eNOS). BAR501, phosphorylates FOXO1 and inhibits ET-1 transcription in liver sinusoidal cells. CONCLUSIONS: BAR501, a UDCA-like GPBAR1 agonist, rescues from endothelial dysfunction in rodent models of portal hypertension by exerting genomic and non-genomic effects on CSE, eNOS and ET-1 in liver sinusoidal cells.
format Online
Article
Text
id pubmed-4634759
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-46347592015-11-13 Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H(2)S Generation and Endothelin-1 Renga, Barbara Cipriani, Sabrina Carino, Adriana Simonetti, Michele Zampella, Angela Fiorucci, Stefano PLoS One Research Article BACKGROUND: GPBAR1 is a bile acids activated receptor expressed in entero-hepatic tissues. In the liver expression of GPBAR1 is restricted to sinusoidal and Kuppfer cells. In the systemic circulation vasodilation caused by GPBAR1 agonists is abrogated by inhibition of cystathione-γ-liase (CSE), an enzyme essential to the generation of hydrogen sulfide (H(2)S), a vasodilatory agent. Portal BAR501 is a semisynthetic bile acid derivative endowed with a potent and selective agonistic activity toward GPBAR1. METHODS: Cirrhosis was induced in mice by carbon tetrachloride (CCL(4)) administration for 9 weeks. Liver endothelial dysfunction was induced by feeding wild type and Gpbar1(-/-) mice with methionine for 4 weeks. In both models, mice were administered BAR501, 15 mg/kg/day. RESULTS: By transactivation assay we demonstrate that BAR501 is a selective GPBAR1 agonist devoid of any FXR agonistic activity. In naïve rats, BAR501 effectively reduced hepatic perfusion pressure and counteracted the vasoconstriction activity of norepinephrine. In the CCl(4) model, 9 weeks treatment with BAR501 effectively protected against development of endothelial dysfunction by increasing liver CSE expression and activity and by reducing endothelin (ET)-1 gene expression. In mice feed methionine, treatment with BAR501 attenuated endothelial dysfunction and caused a GPBAR1-dependent regulation of CSE. Using human liver sinusoidal cells, we found that modulation of CSE expression/activity is mediated by both genomic (recruitment of CREB to CRE in the CSE promoter) and non-genomic effects, involving a Akt-dependent phosporylation of CSE and endothelial nitric oxide (NO) synthase (eNOS). BAR501, phosphorylates FOXO1 and inhibits ET-1 transcription in liver sinusoidal cells. CONCLUSIONS: BAR501, a UDCA-like GPBAR1 agonist, rescues from endothelial dysfunction in rodent models of portal hypertension by exerting genomic and non-genomic effects on CSE, eNOS and ET-1 in liver sinusoidal cells. Public Library of Science 2015-11-05 /pmc/articles/PMC4634759/ /pubmed/26539823 http://dx.doi.org/10.1371/journal.pone.0141082 Text en © 2015 Renga et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Renga, Barbara
Cipriani, Sabrina
Carino, Adriana
Simonetti, Michele
Zampella, Angela
Fiorucci, Stefano
Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H(2)S Generation and Endothelin-1
title Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H(2)S Generation and Endothelin-1
title_full Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H(2)S Generation and Endothelin-1
title_fullStr Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H(2)S Generation and Endothelin-1
title_full_unstemmed Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H(2)S Generation and Endothelin-1
title_short Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H(2)S Generation and Endothelin-1
title_sort reversal of endothelial dysfunction by gpbar1 agonism in portal hypertension involves a akt/foxoa1 dependent regulation of h(2)s generation and endothelin-1
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634759/
https://www.ncbi.nlm.nih.gov/pubmed/26539823
http://dx.doi.org/10.1371/journal.pone.0141082
work_keys_str_mv AT rengabarbara reversalofendothelialdysfunctionbygpbar1agonisminportalhypertensioninvolvesaaktfoxoa1dependentregulationofh2sgenerationandendothelin1
AT ciprianisabrina reversalofendothelialdysfunctionbygpbar1agonisminportalhypertensioninvolvesaaktfoxoa1dependentregulationofh2sgenerationandendothelin1
AT carinoadriana reversalofendothelialdysfunctionbygpbar1agonisminportalhypertensioninvolvesaaktfoxoa1dependentregulationofh2sgenerationandendothelin1
AT simonettimichele reversalofendothelialdysfunctionbygpbar1agonisminportalhypertensioninvolvesaaktfoxoa1dependentregulationofh2sgenerationandendothelin1
AT zampellaangela reversalofendothelialdysfunctionbygpbar1agonisminportalhypertensioninvolvesaaktfoxoa1dependentregulationofh2sgenerationandendothelin1
AT fioruccistefano reversalofendothelialdysfunctionbygpbar1agonisminportalhypertensioninvolvesaaktfoxoa1dependentregulationofh2sgenerationandendothelin1